Biochem/physiol Actions

Target IC₅₀: 50 pM inhibiting the mammalian target of rapamycin (mTOR) and blocking the subsequent activation of p70 S6 kinase

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetMammalian target of rapamycin (mTOR)

General description

Selectively inhibits the phosphorylation and activation of p70 S6 kinase (IC₅₀ = 50 pM). Prevents the translational activation of IGF-II. Also prevents resting T-cells from entering the cell cycle, but does not directly arrest cell cycle progression. Shown to inhibit later signaling events, such as p110Rb phosphorylation, p34cdc2 kinase activation, and cyclin A synthesis. Exhibits strong binding to FK-506 binding proteins. Also reported to induce apoptosis in a murine B-cell line, to inhibit lymphokine-induced cell proliferation at the G₁ phase, and to irreversibly arrest Saccharomyces cerevisiae cells in the G₁ phase.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Packaging

1 mg in Plastic ampoule

Packaged under inert gas

500 µg in Plastic ampoule

Physical form

A 5 mM (500 µg/109 µl) solution of Rapamycin (Cat. No. 553210) in DMSO.

Reconstitution

Following initial use, aliquot and freeze (-20°C).

Warning

Toxicity: Irritant (B)